dc.contributor.author | Lysaght, Joanne | en |
dc.contributor.author | Ravi, Narayanasamy | en |
dc.contributor.author | Reynolds, John | en |
dc.contributor.author | Conroy, Melissa | en |
dc.date.accessioned | 2024-05-27T08:38:54Z | |
dc.date.available | 2024-05-27T08:38:54Z | |
dc.date.issued | 2023 | en |
dc.date.submitted | 2023 | en |
dc.identifier.citation | Davern M, Donlon NE, O'Connell F, Gaughan C, O'Donovan C, Habash M, Sheppard AD, MacLean M, Dunne MR, Moore J, Temperley H, Conroy MJ, Butler C, Bhardwaj A, Ravi N, Donohoe CL, Reynolds JV, Lysaght J., Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients, Cancer Immunology Immunotherapy, 2023 | en |
dc.identifier.other | Y | en |
dc.description | PUBLISHED | en |
dc.description.abstract | Tumour acidosis contributes to cancer progression by inhibiting anti-tumour immunity. However, the effect of acidosis on anti-tumour T cell phenotypes in oesophageal adenocarcinoma (OAC) is unknown. Therefore, this study investigated the effect of acidosis on anti-tumour T cell profiles and if immune checkpoint blockade (ICB) could enhance anti-tumour T cell immunity under acidosis. Acidic conditions substantially altered immune checkpoint expression profiles of OAC patient-derived T cells, upregulating TIM-3, LAG-3 and CTLA-4. Severe acidosis (pH 5.5) significantly decreased the percentage of central memory CD4+ T cells, an effect that was attenuated by ICB treatment. ICB increased T cell production of IFN-γ under moderate acidosis (pH 6.6) but not severe acidosis (pH 5.5) and decreased IL-10 production by T cells under severe acidic conditions only. A link between lactate and metastasis was also depicted; patients with nodal metastasis had higher serum lactate levels (p = 0.07) which also positively correlated with circulating levels of pro-angiogenic factor Tie-2. Our findings establish that acidosis-induced upregulation of immune checkpoints on T cells may potentially contribute to immune evasion and disease progression in OAC. However, acidic conditions curtailed ICB efficacy, supporting a rationale for utilizing systemic oral buffers to neutralize tumour acidity to improve ICB efficacy. Study schematic-PBMCs were isolated from OAC patients (A) and expanded ex vivo for 7 days using anti-CD3/28 +IL-2 T cell activation protocol (B) and further cultured for 48 h under increasing acidic conditions in the absence or presence of immune checkpoint blockade (nivolumab, ipilimumab or dual nivolumab + ipilimumab) (C). Immunophenotyping was then carried out to assess immune checkpoint expression profiles and anti-tumour T cell phenotypes (D). Serum lactate was assessed in OAC patients (E-F) and levels were correlated with patient demographics (G) and the levels of circulating immune/pro-angiogenic cytokines that were determined by multiplex ELISA (H). Key Findings-severe acidic conditions upregulated multiple immune checkpoints on T cells (I). Efficacy of ICB was curtailed under severe acidic conditions (J). Circulating lactate levels positively correlated with circulating levels of pro-angiogenic factor tie-2 and higher serum lactate levels were found in patients who had nodal metastasis (K). | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Cancer Immunology Immunotherapy | en |
dc.rights | Y | en |
dc.subject | A2aR; Acidosis; Immune checkpoints; Lactate; Oesophageal adenocarcinoma; Tie-2 | en |
dc.title | Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/jlysaght | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/meconroy | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/reynoljv | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/ravin | en |
dc.identifier.rssinternalid | 246644 | en |
dc.identifier.doi | https://doi.org/10.1007/s00262-022-03228-y | en |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Cancer | en |
dc.subject.TCDTheme | Immunology, Inflammation & Infection | en |
dc.subject.TCDTag | CANCER | en |
dc.subject.TCDTag | Tumour immunology and immunotherapy | en |
dc.identifier.rssuri | https://doi.org/10.1007/s00262-022-03228-y | |
dc.identifier.orcid_id | 0000-0003-3363-3763 | en |
dc.status.accessible | N | en |
dc.identifier.uri | http://hdl.handle.net/2262/108499 | |